Toronto, December 19, 2023 – The Canadian Generic Pharmaceutical Association (CGPA) is pleased to release a new report: “International Pricing and Canada’s Generic Prescription Medicines.”

In 2022 (Q4), CGPA commissioned an international pricing analysis using the NAVLIN Global Database by EVERSANA. The parameters of the study and the results of the research are outlined in this report.

Data from EVERSANA’s NAVLIN database shows that public prices for generic medicines that are benefits on provincial drug benefit plans in Canada are 45 percent lower than in the PMPRB11 comparator countries.

There are 37 billion reasons to read it. That’s how many dollars generic medicines save Canadians – every year.

Also highlighted are the details of the renewed pCPA / CGPA pricing agreement, the value of a resilient domestic industry, and the actions needed to protect the supply of prescription medicines for Canadian patients.

We invite you to read it here: https://canadiangenerics.ca/wp-content/uploads/2023/12/CGPA_International-Pricing-and-Canadas-Generic-Prescription-Medicines-2023.pdf